Canaccord Genuity Raises Price Target for BioMarin Pharmaceutical Inc.
Canaccord Genuity has increased its price target for BioMarin Pharmaceutical Inc. from $114 to $117.
Economy · News reference
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.64% to 53,219.55 while the NASDAQ dipped 0.40% to 26,296.20. The S&P 500 also
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Canaccord Genuity has increased its price target for BioMarin Pharmaceutical Inc. from $114 to $117.
FingerMotion, Inc. (Nasdaq: FNGR) announced it has retained outside legal counsel and an independent consultant to review potentially irregular trading patterns in its common stock. The company has obtained trading data from Nasdaq and committed to sharing findings with regulatory authorities. The review is ongoing with no conclusions reached yet.
Pacific Gas and Electric Company is advising customers to avoid using payment kiosks for utility bills to protect against potential scams during the holiday season.
FingerMotion, Inc. has launched a strategic review of its entire business operations in the People's Republic of China, including the potential for a sale, to prioritize its Alberta-based power and computing infrastructure program.
Analyst Mitchell Kapoor of H.C. Wainwright has maintained a 'Hold' rating and a $60 price target for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. is participating in an industrial collaboration focused on the scale-up and commercialization of sustainable oligonucleotide manufacturing technology.